Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Accured Expenses (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Change in Accured Expenses for 11 consecutive years, with -$412015.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 223.48% year-over-year to -$412015.0, compared with a TTM value of $390011.0 through Sep 2025, up 77.4%, and an annual FY2024 reading of $3.3 million, up 813.65% over the prior year.
  • Change in Accured Expenses was -$412015.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.0 million in Q4 2024 and bottomed at -$1.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $49571.1, with a median of $6603.5 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 3081.99% in 2024, then crashed 1078.47% in 2025.
  • Year by year, Change in Accured Expenses stood at -$59168.0 in 2021, then soared by 949.77% to $502792.0 in 2022, then crashed by 119.75% to -$99315.0 in 2023, then soared by 3081.99% to $3.0 million in 2024, then tumbled by 113.91% to -$412015.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for KPRX at -$412015.0 in Q3 2025, -$1.1 million in Q2 2025, and -$1.1 million in Q1 2025.